Design and synthesis of novel peptidomimetics for cancer immunotherapy

Tumor cells benefit from some certain signals, which are referred to as “immune checkpoints”, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an...

Full description

Saved in:
Bibliographic Details
Published inOrganic communications Vol. 13; no. 3; pp. 89 - 102
Main Authors Köse, Ceyda, Uysal, Esra, Yazıcı, Büşra, Dingiş-Birgül, Serap İpek, Tuğay, Zeynep, Yanık, Hamdullah, Tavukcuoglu, Ece, Gülyüz, Sevgi, Akdemir, Atilla, Esendağlı, Güneş, Yılmaz, Özgür, Alptürk, Onur
Format Journal Article
LanguageEnglish
Published Gebze ACG Publications 01.07.2020
Subjects
Apoptosis
Cancer
Cancer immunotherapy
Cell death
Cell proliferation
Immune checkpoint
Immune response
Immune system
Immunotherapy
Leukocytes (mononuclear)
PD-1 protein
PD-L1 protein
Peptidomimetics
Peripheral blood mononuclear cells
Tumor cells
Online AccessGet full text

Cover

More Information
Summary:Tumor cells benefit from some certain signals, which are referred to as “immune checkpoints”, to escape immune-mediated destruction. With that in mind, it is believed that the blockade of these points, such as programmed cell death Ligand-1 (PD-L1) and programmed cell death 1 (PD-1), can restore an adaptative immune response against tumoral cells. In this study, we have designed and synthesized some novel peptidomimetics with a 2-aminobenzathiazole scaffold, which targets the PD-1/PDL-1 pathway. In the viability assay, it was found that these compounds decreased the proliferation of peripheral blood mononuclear cells in the concentration of 10 uM. Overall, our results indicate that these novel compounds are potential checkpoint inhibitors for cancer immunotherapy.
ISSN:1307-6175
1307-6175
DOI:10.25135/acg.oc.86.20.09.1802